High-Quality Survodutide CAS: 2805997-46-8 from China Suppliers - Quality Products from Trusted Factory Manufacturer, Quotes
Product Description
Mechanism & Efficacy
Survodutide is a peptide compound designed as a GLP‑1/GIP/glucagon multi‑receptor agonist under clinical investigation for potential benefits in metabolic regulation, weight management, and glucose control. It is being evaluated in clinical studies for its unique balanced receptor agonism profile.
Dosage & Research Use
Typical Human Clinical Dose (Investigational):
Once‑weekly subcutaneous administration is the regimen used in human Phase 2/3 studies.
Commonly studied doses include 2 mg, 4 mg, 6 mg, and 8 mg per week, with dose escalation based on tolerability and clinical endpoints.
These doses are for research purposes only and should only be administered under authorized clinical protocols.
Patent & Intellectual Property
Unlike some established peptide drugs with long‑standing granted patents, Survodutide’s patent landscape is still evolving. Careful review of publicly available patent databases reveals pending patent applications related to multi‑agonist peptide compositions and methods of use, but no single fully granted, composition‑of‑matter patent for Survodutide with a confirmed expiration date is currently available in the public domain.
What is the mechanism of Survodutide?
Survodutide is a peptide compound designed as a GLP-1/GIP/glucagon multi-receptor agonist.
What are the potential benefits being investigated for Survodutide?
It is currently under clinical investigation for potential benefits in metabolic regulation, weight management, and glucose control.
How is Survodutide administered in clinical studies?
The regimen used in human Phase 2/3 studies is a once-weekly subcutaneous administration.
What are the commonly studied doses for Survodutide?
Commonly studied doses in clinical settings include 2 mg, 4 mg, 6 mg, and 8 mg per week, with dose escalation based on tolerability and clinical endpoints.
Is Survodutide available for general medical use?
No, the compound and the mentioned doses are for research purposes only and should exclusively be administered under authorized clinical protocols.
What is the current patent status of Survodutide?
The patent landscape for Survodutide is still evolving. While there are pending patent applications related to multi-agonist peptide compositions and methods of use, there is currently no single fully granted, composition-of-matter patent with a confirmed expiration date in the public domain.
